PUBLISHER: Roots Analysis | PRODUCT CODE: 1267646
PUBLISHER: Roots Analysis | PRODUCT CODE: 1267646
In the last few years, several countries across the globe have legalized the use of medical cannabis and recreational / adult-use cannabis. This can be attributed to the therapeutic potential of cannabis and cannabis-infused products that has been acknowledged recently. Studies have shown that cannabis can provide substantial relief from adverse effects, such as chemotherapy-induced nausea and chronic pain associated with multiple sclerosis. In fact, three cannabis-derived prescription medications have already been approved for sale across the US. Further, the recent legalization of cannabis across several countries, including Canada, Germany and Thailand, has prompted several stakeholders to develop and manufacture cannabis-infused products. However, the illicit market with questionable product quality still remains the primary source of cannabis and cannabis-infused products for the masses. Further, the high potency of the cannabinoids and presence of contaminants, including microbes, pesticides, heavy metals and residual solvents in cannabis-infused products, compromise their shelf life as well as the consumer safety. This inherent lack of quality raises various concerns, challenging the future of this market. In order to overcome these challenges, it becomes imperative that cannabis-infused products comply with the regulatory standards, stringent testing protocols to maintain the safety thresholds and protect consumer health. With rise in demand for safe and compliant cannabis-infused products, the cannabis testing market is anticipated to witness steady growth in the upcoming decade, offering various testing solutions to a number of end-users, including cultivators, product manufacturers, and research institutes.
The Cannabis Testing Market: Distribution by Type of Cannabis Tested (Medical Cannabis and Recreational / Adult-use Cannabis), Type of Sample Tested (Flowers, Extracts, Edibles and Other Type of Samples), Company Size (Small, Mid-sized and Large Companies), and Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa): Industry Trends and Global Forecasts, 2023-2035 report features an extensive study of the current market landscape and the likely future potential of the cannabis testing market, over the next 12 years. It highlights the efforts of various stakeholders engaged in this rapidly emerging segment of the cannabis testing industry. Key inclusions of the report are briefly discussed below.
There has been a steady increase in the consumption of cannabis, also known as marijuana; since 2018, the number of young-adults consuming the plant in any form has increased by 5%. Moreover, the consumption of cannabis increased by 20% during the COVID-19 pandemic. Presently, many countries have legalized medicinal use of cannabis, while 10 such countries have also approved recreational use of the plant. According to the National Organization for the Reform of Marijuana Laws, there were at least 21 US states and District of Columbia that have legalized medical cannabis or adult-use cannabis. Consequently, there is an increasing demand for a diverse range of cannabis-infused products (in terms of applications, medical or recreational), including tinctures, salves, edibles, vape oils and raw plant materials. In order to ensure the quality of different cannabis-infused products, over 350 cannabis testing labs equipped with novel equipment and software have been established globally. These cannabis testing labs provide regulatory-compliant testing of the products, ensuring quality and consumer safety. All these developments have paved way for growth in the cannabis / marijuana testing market.
The recent legalization of medicinal cannabis across the US and many other regions, coupled with the decriminalization of the plant for recreational use, has revolutionized the field. Stringent regulatory standards have been imposed in order to ensure the quality of the product and safety of consumers. To comply with these regulatory standards, an increasing number of cultivators, manufacturers and research institutes are leveraging the superior technical expertise of cannabis testing labs. These service providers offer analysis along with options for testing multiple product samples / final products with quick turnaround times, aiding the quality compliance of the products, as well as fortifying consumer safety. In some US states, such as Massachusetts, the cannabis testing labs have also come together to form an association, showing their responsibility towards building a safe market for the consumers.
The cannabis testing market features more than 160 companies that claim to possess the necessary technical expertise for providing testing services for cannabinoid potency and contaminants, catering to the biopharmaceutical, agricultural and food industries. The market is currently dominated by small companies (1-50 employees), which represent 44% of the total number of players. It is interesting to highlight that companies testing medical-grade cannabis products represent more than 75% of the total players in this market. In addition, recent developments in this industry indicates that substantial number of analytical laboratories have included testing of recreational / adult-use cannabis in their service portfolios. In June 2022, Trichome Analytical became the first cannabis testing lab to receive license for adult-use cannabis testing in New Jersey. In the same month, Bia Diagnostics received license for adult-use cannabis testing in the state of Vermont, which legalized the use of adult-use cannabis in 2018, but the adult-use dispensaries started selling marijuana for recreational purpose in October 2022.
It is also worth highlighting that close to 40 companies world-wide offer cannabis testing products, including analytical instruments, consumables, reagents, and software solutions to these cannabis testing labs. Notably, more than 25% of these players also offer cannabis testing services along with testing products. The increasing number of cannabis testing labs across the world, serving the growing cannabis market, will drive the market to grow at a CAGR of ~22% over the forecast period.
The legalization of cannabis across the globe has led to an increase in the number of cannabis products that comply with regulatory requirements and are safe for human consumption. However, the testing protocols for such products are not standardized across different labs. In addition to this, the market is witnessing various kinds of matrices including candles, edibles, transdermal patches and e-liquids infused with cannabis, which needs a different testing procedure to be followed. This results in inconsistent testing results, compromising the product quality and subsequently, consumer safety. While service providers are striving to tackle these challenges through innovation in design and standardization of methods, the increasing costs of procuring novel equipment and ensuring that they align with the customers' budget, remain a pressing concern. Stringent regulations, including lab accreditations, will be imperative to ensure consumer safety, specifically in the next 2-3 years as medical cannabis / adult-use cannabis is being legalized in several countries. However, these can restrict the market growth potential of cannabis testing labs.
Driven by the rising demand for novel cannabis-infused medicinal and recreational products, the cannabis testing services market is anticipated to witness noteworthy growth in the foreseen future. Specifically, in terms of type of cannabis tested, the market is anticipated to be driven by the high demand for medicinal cannabis. Currently, majority of the revenues are generated from the testing of flower samples; however, in the near future, market for testing extracts and edibles is anticipated to grow at a relatively higher CAGR.
At present there are limited cannabis testing labs in the emerging markets of Latin America, Asia-Pacific, and Africa. South Africa's first cannabis testing lab was opened by Afriplex in March 2019. Since then, several other laboratories like Qure and CannaLab have set up operations in the country. In Latin America, Colombia is anticipated to cater over 40% of the global medical cannabis demand. Presently, under Asia-Pacific, Australia legalized the use of cannabis for recreational applications in 2016; Thailand legalized the plant for medical use in 2018. Following this, it is expected that more countries across the region will legalize the plant for either medical or recreational use in the foreseen future.
Although North America holds the largest share of the cannabis testing market at present, the emerging markets will push the market growth as these markets look to regulate their cannabis industry.
In recent years, the cannabis testing market has witnessed various innovations in testing equipment as well as integration of software solutions in the laboratory workflow. Novel techniques, such as chromatographic methods in parallel with UV spectrometric analysis, improve the overall accuracy and sensitivity of the analytical assays. The integration of laboratory information management systems (LIMS) enables better customer relationship management, enterprise resource management, and overall product outcomes. Moreover, it offers uniform testing results, improved adherence to the regulatory standards, and a higher rate of efficiency. Further, stakeholders in this market have forged several strategic alliances in order to enhance their existing service portfolios and consolidate their presence within the industry. It is worth highlighting that most of these partnership agreements inked were mergers and acquisitions of other key players in the industry. For instance, in January 2023, GrowerIQ partnered with High North Laboratories, to improve the testing processes offered by High North enabling the seamless testing and regular data integration with GrowerIQ's digital record.
Examples of key players engaged in this market (which have also been captured in this report) include Abko Labs, ACT Laboratories, BelCosta Labs, CDX Analytics, Digipath, LGC, Medicinal Genomics, SGS, Steep Hill and Tentamus.
One of the key objectives of the report was to estimate the current opportunity and the future growth potential of the cannabis testing market over the coming years. We have provided an informed estimate on the likely evolution of the market for the period 2023-2035. Our year-wise projections of the current and forecasted opportunity have been further segmented based on relevant parameters, such as type of cannabis tested (medical cannabis and recreational / adult-use cannabis), type of sample tested (flowers, extracts, edibles and other types of samples), company size (small, mid-sized and large companies), and key geographical regions (North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa). In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic scenarios of the industry's evolution.
The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this industry. The report features detailed transcripts of interviews held with the following individuals (in alphabetical order):
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
The data presented in this report was gathered via primary and secondary research. For all our projects, we conduct interviews / surveys with reputed industry experts (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Wherever possible, the available data has been checked for accuracy from multiple sources of information.
While the focus has been on forecasting the market till 2035, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.
Answer: The consumption of cannabis has shown therapeutic efficacy against chronic pain associated with cancer, chemotherapy-induced nausea, epilepsy and multiple sclerosis. Moreover, the plant has also been used to treat certain neurodegenerative disorders including Tourette syndrome, Huntington's disease, Parkinson's disease, post-traumatic stress syndrome (PTSD), anxiety, depression as well as sleep disorders.
Answer: Examples of countries that have legalized the use of cannabis for medical purposes include Argentina, Australia, Canada, Chile, Colombia, Croatia, Cyprus, Czechia, Denmark, Finland, Germany, Greece, Israel, Italy, Jamaica, Lesotho, Luxembourg, Macedonia, Malta, Mexico, the Netherlands, Norway, Peru, Poland, Romania, San Marino, Switzerland, Turkey, Uruguay, the US and Zimbabwe.
Answer: Presently, more than 160 companies are engaged in providing cannabis testing services worldwide. Examples of top players engaged in this market (which have also been captured in this report) include Abko Labs, ACT Laboratories, BelCosta Labs, CDX Analytics, Digipath, LGC, Medicinal Genomics, SGS, Steep Hill and Tentamus.
Answer: The factors driving the cannabis testing market include increasing legalization of cannabis across different regions and surge in demand for novel biopharmaceuticals and other products infused with cannabis extracts, such as tinctures and gummies.
Answer: North America captures around 58% share in the current cannabis testing services market. It is worth highlighting that Asia-Pacific is anticipated to grow at the highest growth rate.
Answer: Currently, in terms of the type of sample tested, flower samples capture the largest share of this market. However, extracts are likely to witness higher annual growth rates in the upcoming years, owing to their more demand and increased utilization in different cannabis-infused products. Further, in terms of the type of cannabis tested, medical cannabis is anticipated to capture a prominent share of the current and future market.
Answer: The cannabis testing services market size is projected to grow at a CAGR of ~22% in the coming years.
Answer: The legalization of cannabis has witnessed a substantial traction in the last few decades. In fact, the demand for medicinal cannabis and recreational cannabis-infused products has also increased. In order to ensure that these products are compliant with the regulatory standards and testing protocols run within the precise time limits with optimized accuracy, several players have integrated software solutions in the laboratory workflow that offer various additional benefits, such as laboratory information management, improving customer relationship and increasing the overall productivity of the labs by reducing turnaround times.
North America
North America